Cytomegalovirus (CMV) latency is associated with severity of joint destruction in rheumatoid arthritis (RA). A prospective observational cohort study (n = 71 at baseline, n = 43 at 21–24 week follow-up) of patients beginning DMARD therapy for early RA found a correlation between the change in 28-joint disease activity score (DAS28) and peripheral blood mononuclear cell (PBMC) cytokine production profiles in response to incubation with human CMV and Epstein–Barr virus. The study validates the idea that immune response profiling could be used to predict patient treatment outcome.
References
Davis, J. M. et al. Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity. Arthritis Res. Ther. 10.1186/ar4389
Rights and permissions
About this article
Cite this article
Viral immunity affects RA treatment. Nat Rev Rheumatol 10, 2 (2014). https://doi.org/10.1038/nrrheum.2013.193
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2013.193